Thus, the cardioprotective effects mediated by GLP-1 analogs via receptor mechanisms in the heart and the endothelium has designated GLP-1 as a potential line of treatment in DCM [22,41,104,105,106,107,108,109,110,111]. The gene discussed is GCG; the disease is familial dilated cardiomyopathy.